Drug intelligence / Profile preview

LY3537031

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

LY3537031 is an investigational peptide-based drug developed by Eli Lilly for the treatment of obesity and overweight. It acts as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide 1 receptor (GLP-1R), similar to other drugs in this class such as tirzepatide. The drug is administered subcutaneously and is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and effects on body weight in overweight, obese, and healthy participants[2][3][4][5]. Its mechanism involves stimulating both GIPR and GLP-1R pathways to improve metabolic control.

Other names: GIP receptor agonist

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on LY3537031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3537031.

Explore the full profile